drugset
drugset / Trial / NCT05877664

Study of ZG0895.HCl in Patients With Advanced Solid Tumors

NCT05877664 ↗

Phase 1 Unknown 60 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the tolerability and safety of ZG0895.HCl, and to assess the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of ZG0895.HCl.

Timeline

Start
2023-08-08
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ZG0895 Unknown 0.06 mg/m2 Subcutaneous
Subject ZG0895 Unknown 0.12 mg/m2 Subcutaneous
Subject ZG0895 Unknown 0.18 mg/m2 Subcutaneous
Subject ZG0895 Unknown 0.37 mg/m2 Subcutaneous
Subject ZG0895 Unknown 0.75 mg/m2 Subcutaneous
Subject ZG0895 Unknown 1.5 mg/m2 Subcutaneous
Subject ZG0895 Unknown 2.25 mg/m2 Subcutaneous
Subject ZG0895 Unknown 3 mg/m2 Subcutaneous
Subject ZG0895 Unknown 3.75 mg/m2 Subcutaneous

Indications

No indication recorded.